Organization (Academic)
Ewha Womans University
ClinicalTrials.gov lists Ewha Womans University as lead sponsor of 74 trials, counting the companies grouped under it. Ewha Womans University itself has 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Ewha Womans University and 2 companies grouped under it: 74 lead-sponsored trials (41 its own, 33 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Ewha Womans University Mokdong Hospital | 28 | 1 |
| Ewha Womans University Seoul Hospital | 5 | 1 |
Disease areas (116)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Osteoarthritis | 16 |
| Atrial Fibrillation | 10 |
| Coronary Artery Disease | 7 |
| Coronary Disease | 7 |
| Stroke | 7 |
Showing 5 of 116 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 29 years.
Recruitment duration, a model prediction: none of the 41 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| N Acetylcysteine | 2 |
| Lithium | 1 |
| Pneumococcal polysaccharide vaccine | 1 |
| Bupropion, Escitalopram | 1 |
| Escitalopram | 1 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | 0 of 1 on time (n=1) |
Journals published in (152)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical orthopaedics and related research | 7 |
| The New England journal of medicine | 7 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 6 |
| The Journal of arthroplasty | 6 |
| European heart journal | 5 |
Showing 5 of 152 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 0 | 2007-04-03 |
Organization relationships (57)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Samsung (South Korea) | Co sponsors trial with | 8 |
| Kyunghee University Medical Center | Co sponsors trial with | 8 |
| Soonchunhyang University Hospital | Co sponsors trial with | 7 |
| Hallym University Medical Center | Co sponsors trial with | 7 |
| Yonsei University | Co sponsors trial with | 6 |
Showing 5 of 57 relationships.
Latest dated events (120)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 120 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| MPI | Trial collaborator | Named in trial inclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
| DLD | Trial collaborator | Named in trial exclusion criteria |
| H6PD | Trial collaborator | Named in trial exclusion criteria |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (257)
Shown in this order: most publications first.
Showing 5 of 257 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.